Bionovo to Present Recent Findings of BZL101, Its Anti-cancer,Agent, at the American Association of Cancer Research ( EMERYVILLE Calif. April 16 2007 /PR...)

Bionovo to Present Recent Findings of BZL101, Its Anti-cancer,Agent, at the American Association of Cancer Research

EMERYVILLE, Calif., April 16, 2007 /PRNewswire-FirstCall/ -- Bionovo, Inc. will present findings on the mechanism of action of its anti-cancer agent BZL101, which is advancing to Phase 1/2 clinical testing for late stage breast cancer at the American Association of Cancer Research (AACR) being held at the Los Angeles Convention Center in Los Angeles, CA, April 14 - 17, 2007.

Bionovo's poster presentation will describe the pathway for cancer cell apoptosis (cell death) induced by BZL101 while leaving normal cells unaffected. As explained by Dr. Emma Shtivelman, Director of Cancer Research at Bionovo, the ability of BZL101 to induce apoptosis is due to attenuation of mitochondrial transmembrane potential (MTP) leading to the release of reactive oxygen species, causing inhibition of glycolysis and ending with induction of oxidative DNA damage.

A paper on BZL101's mechanism of action and unique selective properties based on the company's initial Phase 1 clinical trial was published late last year in the peer-reviewed journal, Breast Cancer Research and Treatment.

"BZL101's mechanism of action and unique selective properties" said Dr. Isaac Cohen, President and CEO of Bionovo, "are a result of some of the biological differences between cancer cells and normal cells. We are hoping that capitalizing on the difference will result in a safe and effective treatment for cancer."

Bionovo, Inc.

Bionovo is a drug development company focusing on the discovery of novel pharmaceutical agents for cancer and women's health. The company has two drugs in clinical testing. MF101 is in Phase 2 for quality of life conditions associated with menopause, and BZL101 is in Phase 1/2 for the treatment of advanced breast cancer. The company has an additional pipeline of drugs in development for breast cancer, pancreatic cancer and other menopausal symptoms with a total of 4 drug candidates expected to be in
'"/>

Page: 1 2 3
Related medicine technology :

1. Bionovos MF101 Shows Positive Safety, Tolerability and Efficacy in Phase 2 Trial
2. The Past, Present and Future of HLA Typing
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
9. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
11. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference

Post Your Comments:

(Date:12/15/2009)... Varian Medical Systems (NYSE: VAR ) announced ... of fiscal year 2010 following the close of regular ... release will be followed by a teleconference available to ... news release and a link to the conference call ... www.varian.com/investor . To access the teleconference call ...

(Date:12/15/2009)... Masimo (Nasdaq: MASI ), the ... Low Perfusion pulse oximetry, today announced that Masimo ... the 2009 Frost & Sullivan CEO of the ... market. According to Frost & Sullivan, the award ... ability in understanding customer requirements, developing new technologies, ...

(Date:12/15/2009)... HAVEN, Conn., Dec. 15 Rib-X Pharmaceuticals, ... and commercialization of novel drugs for the treatment ... entered into a collaborative research agreement with Massachusetts ... science plan for the collaboration, Dr. David Hooper ... in an established animal model to determine resistance ...

[0] Varian Medical Systems Schedules First Quarter FY2010 News Release and Conference Call [0] Masimo Chairman and CEO Joe Kiani Receives 2009 Frost & Sullivan CEO of the Year Award [0] Rib-X Pharmaceuticals Enters into Collaborative Agreement on Delafloxacin with Massachusetts General Hospital

... 2007 /PRNewswire-FirstCall/ - Research,collaborators with Oncolytics Biotech ... presentation covering REOLYSIN(R),clinical trial data at the ... to be held June 1-5, 2007 in ... U.K. Phase I systemic,administration trial. , The ...

... 2007 - A therapeutic,vaccine developed by the ... new hope for cancer patients. The results ... presented to an,international audience at the Annual ... (ASCO) in Chicago, USA. ASCO is the,most ...

Other Medicine Technology:Oncolytics Biotech Inc.'s Research Collaborators to Present,REOLYSIN Clinical Trial Data at ASCO Conference 2 Vakzine Projekt Management Reports Positive Clinical Trial Results,With Their Therapeutic Prostate Cancer Vaccine VPM4001 2

Oncolytics Biotech Inc.'s Research Collaborators to Present,REOLYSIN Clinical Trial Data at ASCO Conference Vakzine Projekt Management Reports Positive Clinical Trial Results,With Their Therapeutic Prostate Cancer Vaccine VPM4001

(Date:12/14/2009)... Ga., Dec. 14 Aflac Incorporated announced ... value) of thirty-year senior notes with a coupon ... a price of 98.951 to yield 6.984%. The ... for debt repayment and general corporate purposes. ,, ... Aflac Incorporated President and Chief Financial Officer Kriss ...

(Date:12/14/2009)... CULVER CITY, Calif., Dec. 14 United Dental ... is one of the providers of top-notch dental care ... cosmetic dentistry, restorative dentistry, kid,s dentistry, braces (orthodontics) and ... West Los Angeles Dentist offices are staffed with ... you. ,, Dr. Eftekhari (Dr. E) is ...

(Date:12/14/2009)... one gene, researchers say , , MONDAY, Dec. 14 (HealthDay ... variants in a single gene linked to heart failure. ... in St. Louis analyzed the DNA of a large ... 129 variants in four genes that could be connected ... heart failure and 625 healthy whites led the researchers ...

(Date:12/14/2009)... 13 years under government controlled health care, before moving to the ... engagements and in his new book, Health Reform: The End of ... a system and its threat to real health care! , ... ... a diagnostic radiologist from Minnesota, warns Americans not to sell out ...

(Date:12/14/2009)... from common CT procedures vary widely and are higher than generally ... new study led by University of California, San Francisco (UCSF) ... ... December 14, 2009 -- Radiation doses from common CT procedures vary ... risk for cancer, according to a new study led by University ...

Breaking Medicine News(10 mins):Health News:Aflac Incorporated Prices $400 Million of 30-Year Senior Notes 2 Health News:Aflac Incorporated Prices $400 Million of 30-Year Senior Notes 3 Health News:Aflac Incorporated Prices $400 Million of 30-Year Senior Notes 4 Health News:United Dental Care, Gentle Care, Trusted Dentists 2 Health News:United Dental Care, Gentle Care, Trusted Dentists 3 Health News:Canadian Doctor Warns Against Government-Run, Socialized Medicine and its Threat to Health Care and Freedom in America 2 Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 2 Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 3 Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 4 Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 5

[0] Aflac Incorporated Prices $400 Million of 30-Year Senior Notes [0] United Dental Care, Gentle Care, Trusted Dentists [0] Contributors to Heart Failure Identified [2] Canadian Doctor Warns Against Government-Run, Socialized Medicine and its Threat to Health Care and Freedom in America [0] Variable Doses of Radiation Raise Safety Concerns for CT Procedures

... 4 SAFC Pharma(TM), a focus,area within SAFC(R) ... (Nasdaq: SIAL ), today officially announced details,of ... (Wisconsin) facility,designed to significantly increase its capacity to ... The investment,includes the purchase of 15 acres of ...

... Entire Region Won,t Succumb to the Pressure, ORLANDO, Fla., ... High Blood Pressure in our lifetime, but that data doesn,t ... to fight the,silent killer. Today, Orlando Mayor Buddy Dyer was ... first of its kind health,initiative to promote healthier outcomes for ...

... Secretary Mike,Leavitt today welcomed 11 more community collaborations ... care system where consumers, providers,and payers make decisions ... These communities will join 14 others as ... care providers, employers,insurers, and consumers working jointly to ...

... levels triple risk of aggressive disease , , WEDNESDAY, Sept. ... fall within the high end of the normal range ... cancer, a new report shows. , The results suggest ... cancer, the researchers said. But one expert cautioned against ...

... that individual cells in the immune system use to ... signals the researchers detected originated in dendritic cells ... initial detection of microscopic invaders and were received ... roles in the immune system, including coordination of attacks ...

... grants will be awarded to Texas ... public interest attorneys, AUSTIN, Texas, Sept. 3 ... allotment of grants,totaling more than $24 million, will be distributed to 40 ... TAJF was created by the Supreme Court of Texas and is the ...

Other Medicine News:Health News:SAFC Pharma(TM) Commits to Major Expansion of High Potency API Production at Madison Site 2 Health News:SAFC Pharma(TM) Commits to Major Expansion of High Potency API Production at Madison Site 3 Health News:Mayor Issues Million Resident Challenge To Educate Central Florida About Blood Pressure 2 Health News:Mayor Issues Million Resident Challenge To Educate Central Florida About Blood Pressure 3 Health News:Mayor Issues Million Resident Challenge To Educate Central Florida About Blood Pressure 4 Health News:Mayor Issues Million Resident Challenge To Educate Central Florida About Blood Pressure 5 Health News:Mayor Issues Million Resident Challenge To Educate Central Florida About Blood Pressure 6 Health News:HHS Designates 11 Communities Working to Improve Quality and Value of Health Care As Chartered Value Exchanges 2 Health News:HHS Designates 11 Communities Working to Improve Quality and Value of Health Care As Chartered Value Exchanges 3 Health News:Study Links Serum Calcium, Prostate Cancer Death 2 Health News:Study Links Serum Calcium, Prostate Cancer Death 3 Health News:New nano device detects immune system cell signaling 2 Health News:New nano device detects immune system cell signaling 3 Health News:New nano device detects immune system cell signaling 4 Health News:New nano device detects immune system cell signaling 5 Health News:Texas Access to Justice Foundation Awards More Than $24 Million to Nonprofits Across the State for Legal Aid to Poor 2 Health News:Texas Access to Justice Foundation Awards More Than $24 Million to Nonprofits Across the State for Legal Aid to Poor 3 Health News:Texas Access to Justice Foundation Awards More Than $24 Million to Nonprofits Across the State for Legal Aid to Poor 4

SAFC Pharma(TM) Commits to Major Expansion of High Potency API Production at Madison Site Mayor Issues Million Resident Challenge To Educate Central Florida About Blood Pressure HHS Designates 11 Communities Working to Improve Quality and Value of Health Care As Chartered Value Exchanges Study Links Serum Calcium, Prostate Cancer Death New nano device detects immune system cell signaling Texas Access to Justice Foundation Awards More Than $24 Million to Nonprofits Across the State for Legal Aid to Poor

This table has adjustable height, an integral leg, and blade post. Includes a standard 2" (5 cm) pad....

... designed for use without the ... for full C-Arm access. ... onboard when more stability is ... slide into standard sockets for ...

... rail clamps mount this ... and stretchers. The roller ... for lifting. Easy locking ... surface combined with infinite ...

... The powered torso and ... Orthopedic Trauma Table simultaneously lift ... independent lift mechanism raises and ... for precise positioning. A wide ...

Medicine Products:

Hourglass Table Ultralight 5100 Legless Ultralight 4100HT Roller Base Modular Table System: Ovation™ Orthopedic Trauma Table

( EMERYVILLE Calif. April 16 2007 /PR...)Bionovo to Present Recent Findings of BZL101, Its Anti-cancer,Agent, at the American Association of Cancer Research,Health